NCT01459926

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 217 (actual)
• Sponsor: Theravance Biopharma · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects with Opioid-Induced Constipation

Conditions

• Opioid Induced Constipation

Interventions

Type	Name	Description
DRUG	TD-1211	once daily
DRUG	TD-1211	Once daily
DRUG	TD-1211	Once daily
DRUG	Placebo	Once daily

Timeline

• Start date: 2011-11-01
• Primary completion: 2012-05-01
• Completion: 2012-06-01
• First posted: 2011-10-26
• Last updated: 2021-01-22

Locations

1 site across 1 country: United States